ArticleTherapeutic advances in musculoskeletal disease2026
Association of an app-based intervention with improvements in mobility, trunk muscle strength and patient-reported disease activity in axial spondyloarthritis: a 24-week pre-post study.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In a nationwide randomised controlled trial among 200 axial spondyloarthritis (axSpA) patients, the medical app Axia improved patient-reported disease activity scores, functional status and quality of life. Objective: This companion study aimed to explore Axia's effects on objective parameters such as mobility, strength and imaging. Design: Single-centre, two-phase pre-post intervention study over 24 weeks. Methods: Thirty-two patients with axSpA on stable pharmacotherapy underwent 12 weeks of standard care (phase I) followed by 12 weeks of Axia use (phase II). The primary endpoint was Bath Ankylosing Spondylitis Metrology Index (BASMI) at week 24 (W24) versus week 12 (W12) and baseline. Secondary endpoints included muscle strength, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), safety and magnetic resonance imaging (MRI) of the sacroiliac joints. Results: Twenty-seven (84%) of 32 participants (mean age 49.1 years, 48.1% females and radiographic axSpA, 66.7% biological or targeted synthetic disease-modifying anti-rheumatic drugs therapy) completed the study. During standard care, BASMI (baseline 3.1; W12 3.0; Conclusion: Axia use was associated with improved spinal mobility, extensor strength and disease activity, without relevant safety concerns. Trial registration: The study was registered in the German Clinical Trials Register (DRKS00038067).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.